Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00549) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
Moclobemide
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Drug in Phase 3 Clinical Trial
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4235"></iframe>
|
 |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Inhibited by This Xenobiotics | ||||||
| Monoamine oxidase type A (MAO-A) | DME Info | Homo sapiens | [1] | |||
| Xenobiotics-DME Activity Data | ||||||
| Xenobiotics-DME Activity Data | Monoamine oxidase type A (MAO-A) | DME Info | IC50 = 0.36138 microM | [1] | ||
| References | ||||||
| 1 | Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives. Bioorg Med Chem Lett. 2015 Feb 1;25(3):642-8. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.